

HR 2356

Prescription Drug Comparative Effectiveness Act of 2003

Congress: 108 (2003–2005, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 5, 2003

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 11, 2003)

Official Text: <https://www.congress.gov/bill/108th-congress/house-bill/2356>

Sponsor

Name: Rep. Allen, Thomas H. [D-ME-1]

Party: Democratic • State: ME • Chamber: House

Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bereuter, Doug [R-NE-1]	R · NE		Jun 5, 2003
Rep. Berry, Marion [D-AR-1]	D · AR		Jun 5, 2003
Rep. Bono, Mary [R-CA-45]	R · CA		Jun 5, 2003
Rep. Burton, Dan [R-IN-5]	R · IN		Jun 5, 2003
Rep. Cooper, Jim [D-TN-5]	D · TN		Jun 5, 2003
Rep. Davis, Jim [D-FL-11]	D · FL		Jun 5, 2003
Rep. Emerson, Jo Ann [R-MO-8]	R · MO		Jun 5, 2003
Rep. Gutknecht, Gil [R-MN-1]	R · MN		Jun 5, 2003
Rep. Snyder, Vic [D-AR-2]	D · AR		Jun 5, 2003
Rep. Wamp, Zach [R-TN-3]	R · TN		Jun 5, 2003
Rep. Waxman, Henry A. [D-CA-30]	D · CA		Jun 5, 2003
Rep. Brown, Sherrod [D-OH-13]	D · OH		Jul 9, 2003
Rep. Ehlers, Vernon J. [R-MI-3]	R · MI		Oct 30, 2003
Rep. Green, Gene [D-TX-29]	D · TX		Oct 30, 2003
Rep. Kingston, Jack [R-GA-1]	R · GA		Oct 30, 2003

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 11, 2003

Subjects & Policy Tags

Policy Area:

Health

## Related Bills

---

*No related bills are listed.*

## Summary (as of Jun 5, 2003)

---

Prescription Drug Comparative Effectiveness Act of 2003 - Directs the Director of the National Institutes of Health, in coordination with the Director of the Agency for Healthcare Research and Quality, to conduct research to develop valid scientific evidence regarding the comparative effectiveness, cost-effectiveness, and (where appropriate) comparative safety relative to other drugs and treatments for the same disease or condition, of prescription drugs that account for high levels of expenditures or use by individuals in Federally funded health programs, including Medicare and Medicaid. Directs the Director of the Agency for Healthcare Research and Quality to: (1) analyze such evidence; and (2) develop standards for the design and conduct of cost-effectiveness studies under this Act.

Establishes reporting requirements.

## Actions Timeline

---

- **Jun 11, 2003:** Referred to the Subcommittee on Health.
- **Jun 5, 2003:** Introduced in House
- **Jun 5, 2003:** Introduced in House
- **Jun 5, 2003:** Referred to the House Committee on Energy and Commerce.